Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 175 results
September 2017
-
Media ReleaseNovartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruptionOPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled[1] Should a treatment pause be necessary, data showed almost…
-
Media ReleaseSandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira®* safety and efficacy profile[1]Sandoz proposed biosimilar adalimumab is currently under…
-
Media ReleaseNovartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety dataCosentyx® (secukinumab) is the first and only fully human IL-17A inhibitor to show sustained skin clearance rates at 5 years in phase III in psoriasis[1] Landmark data show that PASI…
-
Media ReleaseSandoz proposed biosimilar rituximab accepted for review by the FDARituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis[1] Sandoz believes the comprehensive data package submitted to the FDA for review confirms…
July 2017
-
Media ReleaseQ2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative productsNet sales in line with prior year (0% cc[1], -2% USD), as growth drivers offset Gleevec/Glivec Gx impact: Cosentyx (USD 490 million, +90% cc) continues strong growth in all three indications…
-
Media ReleaseNovartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis5 year data from long-term Phase III extension study demonstrate sustained efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis[1] Data planned to be…
-
Media ReleaseNovartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasisLabel update includes 52 week data from CLEAR study demonstrating long-term superiority of Cosentyx® versus Stelara® in psoriasis [1],[2] Update also includes use of Cosentyx in moderate-to…
June 2017
-
Media ReleaseSandoz receives approval in Europe for Erelzi® (biosimilar etanercept) to treat multiple inflammatory diseasesEuropean Commission approves Sandoz Erelzi® to treat immunological diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis Approval of Erelzi provides more treatment options for…
-
Media ReleaseNovartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burdenUrgent need to improve management of chronic urticaria (CU) - a disease that causes itchy, persistent hives and swelling which last more than 6 weeks or recur over months or years - highlighted by…
-
Media ReleaseSandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseasesEuropean Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare…
-
Media ReleaseNovartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their diseaseLarge-scale European patient survey found that 94% of severe allergic asthma patients were unable to fully control their disease These new data underscore the disconnect between self-…
Pagination
- ‹ Previous page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- › Next page